Share Price and Basic Stock Data
Last Updated: January 3, 2026, 11:43 am
| PEG Ratio | 0.78 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kilitch Drugs (India) Ltd, operating in the pharmaceuticals sector, reported a market capitalization of ₹630 Cr, with its share price standing at ₹360. The company has demonstrated notable revenue growth, with sales increasing from ₹114 Cr in FY 2022 to ₹140 Cr in FY 2023, and projected revenues of ₹154 Cr for FY 2024 and ₹198 Cr for FY 2025. Quarterly sales data shows a strong rebound in Q1 FY 2025, with revenues reaching ₹44.82 Cr, up from ₹26.75 Cr in Q2 FY 2022. This upward trend is further supported by a consistent increase in sales over the quarters, peaking at ₹61.23 Cr in March 2025. The reported operating profit margin (OPM) for FY 2025 is 16%, indicating effective cost management and operational efficiency. The company’s ability to adapt to market demands and enhance product offerings has likely contributed to this revenue trajectory, positioning it well within the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Kilitch Drugs has exhibited improving profitability metrics, with a net profit of ₹26 Cr for FY 2025, up from ₹8 Cr in FY 2023. The return on equity (ROE) is reported at 12.6%, while the return on capital employed (ROCE) stands at 15.7%, reflecting efficient use of shareholders’ funds. The operating profit margin (OPM) has shown resilience, recorded at 10.30% in the latest quarter. However, fluctuations in quarterly OPM indicate varying operational efficiencies, ranging from 7.17% in December 2023 to a high of 23.83% in March 2025. The interest coverage ratio (ICR) stands robust at 8.46x, suggesting the company is well-positioned to meet its interest obligations. Despite these strengths, the company faces challenges in maintaining consistent profitability, as evidenced by the decline in net profit margin to 12.57% in FY 2025 from higher levels in previous periods.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kilitch Drugs reflects a solid financial foundation, with total assets amounting to ₹399 Cr as of September 2025. The company holds reserves of ₹248 Cr, which have steadily increased from ₹136 Cr in FY 2023. Borrowings have also risen to ₹84 Cr, indicating a manageable debt level relative to its equity capital of ₹16 Cr. The debt-to-equity ratio is reported at 0.24, indicating a low reliance on debt financing. The current ratio of 2.06 and quick ratio of 1.88 suggest strong liquidity, allowing the company to cover short-term obligations comfortably. Additionally, the price-to-book value (P/BV) ratio stands at 2.87x, which is within a typical range for the pharmaceutical sector, indicating a reasonable valuation relative to its net assets. However, the rise in borrowings may pose a risk if not managed effectively, particularly in a fluctuating interest rate environment.
Shareholding Pattern and Investor Confidence
Kilitch Drugs has a diverse shareholding structure, with promoters holding 63.77% of the company as of September 2025, a slight decline from 69.23% earlier in the year. The public holds 36.22%, indicating a healthy retail investor presence with 10,929 shareholders. This distribution suggests a stable investor base, although the decrease in promoter holding could raise concerns regarding insider confidence. The company has not reported any foreign institutional investment (FII), which might limit broader market engagement. However, the increasing number of public shareholders from 9,000 in September 2023 to over 10,000 in September 2025 reflects growing interest in the company. The lack of significant institutional backing poses a risk, as institutional investors often provide stability and credibility in volatile market conditions.
Outlook, Risks, and Final Insight
The outlook for Kilitch Drugs appears cautiously optimistic, driven by robust revenue growth and improving profitability metrics. However, risks such as fluctuating operational efficiency and reliance on domestic sales could impact future performance. The company must navigate rising competition in the pharmaceuticals sector while managing its increasing debt levels effectively. Additionally, the absence of foreign institutional investment could hinder potential growth opportunities. Should Kilitch Drugs manage to sustain its growth trajectory while improving operational efficiencies, it could enhance its market position significantly. Conversely, failure to address these risks may lead to volatility in performance and investor sentiment. Overall, Kilitch Drugs presents a compelling case for potential investors, particularly those seeking exposure to the Indian pharmaceutical market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.70 | 29.97 | 45.48 | 36.56 | 41.20 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 |
| Expenses | 26.75 | 25.99 | 39.26 | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 |
| Operating Profit | 3.95 | 3.98 | 6.22 | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.10 | 8.73 | 14.59 | 3.26 | 5.04 |
| OPM % | 12.87% | 13.28% | 13.68% | 16.90% | 20.92% | 7.17% | 15.80% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.30% |
| Other Income | 0.24 | 0.69 | 1.02 | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.70 | 2.56 | 6.66 |
| Interest | 1.75 | 1.29 | 1.21 | 1.50 | 1.51 | 1.60 | 1.32 | 1.73 | 0.31 | 1.40 | 1.60 | 1.53 | 1.44 |
| Depreciation | 0.89 | 0.93 | 0.91 | 0.71 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 |
| Profit before tax | 1.55 | 2.45 | 5.12 | 4.53 | 6.78 | 2.83 | 5.30 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 | 9.40 |
| Tax % | -25.16% | 30.61% | 43.16% | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.00% | 26.23% | 34.49% | 14.47% |
| Net Profit | 1.94 | 1.71 | 2.90 | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 |
| EPS in Rs | 1.44 | 1.40 | 2.11 | 1.99 | 2.71 | 1.66 | 2.05 | 0.77 | 4.93 | 3.41 | 5.94 | 1.73 | 4.69 |
Last Updated: December 30, 2025, 6:34 am
Below is a detailed analysis of the quarterly data for Kilitch Drugs (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 48.92 Cr.. The value appears strong and on an upward trend. It has increased from 43.14 Cr. (Jun 2025) to 48.92 Cr., marking an increase of 5.78 Cr..
- For Expenses, as of Sep 2025, the value is 43.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 39.88 Cr. (Jun 2025) to 43.88 Cr., marking an increase of 4.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 5.04 Cr.. The value appears strong and on an upward trend. It has increased from 3.26 Cr. (Jun 2025) to 5.04 Cr., marking an increase of 1.78 Cr..
- For OPM %, as of Sep 2025, the value is 10.30%. The value appears strong and on an upward trend. It has increased from 7.56% (Jun 2025) to 10.30%, marking an increase of 2.74%.
- For Other Income, as of Sep 2025, the value is 6.66 Cr.. The value appears strong and on an upward trend. It has increased from 2.56 Cr. (Jun 2025) to 6.66 Cr., marking an increase of 4.10 Cr..
- For Interest, as of Sep 2025, the value is 1.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.53 Cr. (Jun 2025) to 1.44 Cr., marking a decrease of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 0.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.84 Cr. (Jun 2025) to 0.86 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is 9.40 Cr.. The value appears strong and on an upward trend. It has increased from 3.45 Cr. (Jun 2025) to 9.40 Cr., marking an increase of 5.95 Cr..
- For Tax %, as of Sep 2025, the value is 14.47%. The value appears to be improving (decreasing) as expected. It has decreased from 34.49% (Jun 2025) to 14.47%, marking a decrease of 20.02%.
- For Net Profit, as of Sep 2025, the value is 8.04 Cr.. The value appears strong and on an upward trend. It has increased from 2.27 Cr. (Jun 2025) to 8.04 Cr., marking an increase of 5.77 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.69. The value appears strong and on an upward trend. It has increased from 1.73 (Jun 2025) to 4.69, marking an increase of 2.96.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:05 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108 | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 209 |
| Expenses | 95 | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 178 |
| Operating Profit | 13 | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 32 |
| OPM % | 12% | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 16% | 15% |
| Other Income | 92 | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 13 |
| Interest | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 |
| Depreciation | 5 | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 |
| Profit before tax | 97 | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 35 |
| Tax % | 22% | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | |
| Net Profit | 76 | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 26 |
| EPS in Rs | 52.99 | -0.20 | -7.77 | -6.17 | 3.46 | 2.29 | 0.50 | 2.18 | 4.36 | 6.18 | 8.34 | 15.26 | 15.77 |
| Dividend Payout % | 52% | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 18.18% | 155.56% | -20.00% | -75.00% | 300.00% | 50.00% | 33.33% | 75.00% | 78.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 137.37% | -175.56% | -55.00% | 375.00% | -250.00% | -16.67% | 41.67% | 3.57% |
Kilitch Drugs (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 30% |
| 3 Years: | 20% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 164% |
| 3 Years: | 60% |
| TTM: | 123% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 33% |
| 3 Years: | 30% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 17 |
| Reserves | 101 | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 248 |
| Borrowings | 9 | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 84 |
| Other Liabilities | 54 | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 49 |
| Total Liabilities | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
| Fixed Assets | 9 | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 64 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 98 |
| Investments | 138 | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 77 |
| Other Assets | 30 | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 160 |
| Total Assets | 177 | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 399 |
Below is a detailed analysis of the balance sheet data for Kilitch Drugs (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 186.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 49.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 35.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing). It has decreased from 61.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 399.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 313.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 86.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.00 Cr..
- For CWIP, as of Sep 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 47.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 51.00 Cr..
- For Investments, as of Sep 2025, the value is 77.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 31.00 Cr..
- For Total Assets, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 313.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 86.00 Cr..
Notably, the Reserves (248.00 Cr.) exceed the Borrowings (84.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 4.00 | -2.00 | -4.00 | -2.00 | 5.00 | -2.00 | -13.00 | -10.00 | -10.00 | -4.00 | -8.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 |
| Inventory Days | 12 | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 |
| Days Payable | 19 | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 |
| Cash Conversion Cycle | 44 | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 |
| Working Capital Days | -143 | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 |
| ROCE % | 8% | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Diluted EPS (Rs.) | 16.60 | 9.17 | 6.71 | 4.73 | 2.37 |
| Cash EPS (Rs.) | 17.44 | 10.52 | 7.59 | 5.57 | 3.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 125.81 | 109.62 | 96.64 | 90.03 | 83.56 |
| Revenue From Operations / Share (Rs.) | 123.31 | 95.99 | 89.59 | 73.31 | 44.22 |
| PBDIT / Share (Rs.) | 26.50 | 17.80 | 13.15 | 8.52 | 5.07 |
| PBIT / Share (Rs.) | 24.57 | 15.72 | 10.87 | 6.94 | 3.79 |
| PBT / Share (Rs.) | 21.44 | 12.03 | 7.71 | 6.17 | 3.30 |
| Net Profit / Share (Rs.) | 15.51 | 8.44 | 5.32 | 3.99 | 2.43 |
| NP After MI And SOA / Share (Rs.) | 16.60 | 9.08 | 6.71 | 4.73 | 2.37 |
| PBDIT Margin (%) | 21.49 | 18.54 | 14.67 | 11.62 | 11.47 |
| PBIT Margin (%) | 19.92 | 16.37 | 12.12 | 9.46 | 8.57 |
| PBT Margin (%) | 17.38 | 12.53 | 8.60 | 8.41 | 7.47 |
| Net Profit Margin (%) | 12.57 | 8.79 | 5.93 | 5.43 | 5.49 |
| NP After MI And SOA Margin (%) | 13.46 | 9.45 | 7.48 | 6.44 | 5.35 |
| Return on Networth / Equity (%) | 13.19 | 8.28 | 6.89 | 5.29 | 2.88 |
| Return on Capital Employeed (%) | 17.29 | 14.37 | 11.24 | 7.69 | 4.52 |
| Return On Assets (%) | 8.53 | 6.08 | 4.75 | 3.51 | 1.80 |
| Long Term Debt / Equity (X) | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.24 | 0.17 | 0.14 | 0.14 | 0.11 |
| Asset Turnover Ratio (%) | 0.71 | 0.67 | 0.65 | 0.48 | 0.41 |
| Current Ratio (X) | 2.06 | 2.27 | 1.84 | 1.65 | 1.10 |
| Quick Ratio (X) | 1.88 | 2.21 | 1.81 | 1.57 | 1.05 |
| Inventory Turnover Ratio (X) | 20.55 | 51.18 | 21.16 | 14.04 | 8.31 |
| Interest Coverage Ratio (X) | 8.46 | 4.83 | 4.16 | 11.08 | 10.42 |
| Interest Coverage Ratio (Post Tax) (X) | 5.95 | 3.29 | 2.68 | 6.18 | 5.99 |
| Enterprise Value (Cr.) | 619.00 | 638.35 | 218.65 | 272.89 | 130.24 |
| EV / Net Operating Revenue (X) | 3.12 | 4.14 | 1.57 | 2.39 | 1.90 |
| EV / EBITDA (X) | 14.52 | 22.29 | 10.67 | 20.55 | 16.57 |
| MarketCap / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| Price / BV (X) | 2.87 | 3.56 | 1.43 | 1.88 | 0.98 |
| Price / Net Operating Revenue (X) | 2.93 | 4.06 | 1.56 | 2.29 | 1.83 |
| EarningsYield | 0.04 | 0.02 | 0.04 | 0.02 | 0.02 |
After reviewing the key financial ratios for Kilitch Drugs (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.17 (Mar 24) to 16.60, marking an increase of 7.43.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.44. This value is within the healthy range. It has increased from 10.52 (Mar 24) to 17.44, marking an increase of 6.92.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 125.81. It has increased from 109.62 (Mar 24) to 125.81, marking an increase of 16.19.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 123.31. It has increased from 95.99 (Mar 24) to 123.31, marking an increase of 27.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 26.50. This value is within the healthy range. It has increased from 17.80 (Mar 24) to 26.50, marking an increase of 8.70.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.57. This value is within the healthy range. It has increased from 15.72 (Mar 24) to 24.57, marking an increase of 8.85.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.44. This value is within the healthy range. It has increased from 12.03 (Mar 24) to 21.44, marking an increase of 9.41.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 8.44 (Mar 24) to 15.51, marking an increase of 7.07.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.60. This value is within the healthy range. It has increased from 9.08 (Mar 24) to 16.60, marking an increase of 7.52.
- For PBDIT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has increased from 18.54 (Mar 24) to 21.49, marking an increase of 2.95.
- For PBIT Margin (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has increased from 16.37 (Mar 24) to 19.92, marking an increase of 3.55.
- For PBT Margin (%), as of Mar 25, the value is 17.38. This value is within the healthy range. It has increased from 12.53 (Mar 24) to 17.38, marking an increase of 4.85.
- For Net Profit Margin (%), as of Mar 25, the value is 12.57. This value exceeds the healthy maximum of 10. It has increased from 8.79 (Mar 24) to 12.57, marking an increase of 3.78.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.46. This value is within the healthy range. It has increased from 9.45 (Mar 24) to 13.46, marking an increase of 4.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.19. This value is below the healthy minimum of 15. It has increased from 8.28 (Mar 24) to 13.19, marking an increase of 4.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 14.37 (Mar 24) to 17.29, marking an increase of 2.92.
- For Return On Assets (%), as of Mar 25, the value is 8.53. This value is within the healthy range. It has increased from 6.08 (Mar 24) to 8.53, marking an increase of 2.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.13. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.13, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.24, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has increased from 0.67 (Mar 24) to 0.71, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has decreased from 2.27 (Mar 24) to 2.06, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.88, marking a decrease of 0.33.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.55. This value exceeds the healthy maximum of 8. It has decreased from 51.18 (Mar 24) to 20.55, marking a decrease of 30.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.46. This value is within the healthy range. It has increased from 4.83 (Mar 24) to 8.46, marking an increase of 3.63.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.95. This value is within the healthy range. It has increased from 3.29 (Mar 24) to 5.95, marking an increase of 2.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 619.00. It has decreased from 638.35 (Mar 24) to 619.00, marking a decrease of 19.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 4.14 (Mar 24) to 3.12, marking a decrease of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 14.52. This value is within the healthy range. It has decreased from 22.29 (Mar 24) to 14.52, marking a decrease of 7.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.87, marking a decrease of 0.69.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has decreased from 4.06 (Mar 24) to 2.93, marking a decrease of 1.13.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kilitch Drugs (India) Ltd:
- Net Profit Margin: 12.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.19% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.8 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.24
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | C-301/2, M.I.D.C., New Mumbai Maharashtra 400705 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mukund P Mehta | Managing Director |
| Mr. Bhavin Mukund Mehta | Whole Time Director |
| Mrs. Mira B Mehta | Whole Time Director |
| Mr. Hemang J Engineer | Independent Director |
| Mr. Venkita Subramanian Rajan | Independent Director |
| Prof. Vasudev Krishna Murti | Independent Director |
| Mr. Dipen J Jain | Independent Director |
FAQ
What is the intrinsic value of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's intrinsic value (as of 05 January 2026) is ₹356.32 which is 1.02% lower the current market price of ₹360.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹630 Cr. market cap, FY2025-2026 high/low of ₹500/265, reserves of ₹248 Cr, and liabilities of ₹399 Cr.
What is the Market Cap of Kilitch Drugs (India) Ltd?
The Market Cap of Kilitch Drugs (India) Ltd is 630 Cr..
What is the current Stock Price of Kilitch Drugs (India) Ltd as on 05 January 2026?
The current stock price of Kilitch Drugs (India) Ltd as on 05 January 2026 is ₹360.
What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kilitch Drugs (India) Ltd stocks is ₹500/265.
What is the Stock P/E of Kilitch Drugs (India) Ltd?
The Stock P/E of Kilitch Drugs (India) Ltd is 22.8.
What is the Book Value of Kilitch Drugs (India) Ltd?
The Book Value of Kilitch Drugs (India) Ltd is 152.
What is the Dividend Yield of Kilitch Drugs (India) Ltd?
The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.
What is the ROCE of Kilitch Drugs (India) Ltd?
The ROCE of Kilitch Drugs (India) Ltd is 15.7 %.
What is the ROE of Kilitch Drugs (India) Ltd?
The ROE of Kilitch Drugs (India) Ltd is 12.6 %.
What is the Face Value of Kilitch Drugs (India) Ltd?
The Face Value of Kilitch Drugs (India) Ltd is 10.0.